日前，位于合肥高新區(qū)的安徽中盛溯源生物科技有限公司研發(fā)的“NCR100注射液”獲批臨床，擬開展針對膝骨關(guān)節(jié)炎的臨床試驗(yàn)，這也是國內(nèi)首款獲批臨床的誘導(dǎo)多能干細(xì)胞（iPSC）衍生的間充質(zhì)干細(xì)胞（iMSC）藥物[1]。
圖1 合肥產(chǎn)全國首款干細(xì)胞新藥獲批
膝關(guān)節(jié)炎是中老年人常見的關(guān)節(jié)退行性病變。骨關(guān)節(jié)炎是以關(guān)節(jié)軟骨破壞及關(guān)節(jié)邊緣和軟骨下骨質(zhì)再生為特征的慢性關(guān)節(jié)疾病。本病病理核心是關(guān)節(jié)軟骨的損傷及骨贅形成。目前認(rèn)為本病是多因素聯(lián)合作用的結(jié)果：軟骨基質(zhì)合成與分解代謝失調(diào)，軟骨下骨板損害使軟骨失去緩沖作用，關(guān)節(jié)內(nèi)局灶性炎癥[2]。臨床常見患者膝關(guān)節(jié)的疼痛、晨僵、腫脹、摩擦音及畸形，嚴(yán)重影響了中老年人的生活質(zhì)量。
圖2 膝關(guān)節(jié)炎病因
一些因子抑制半胱氨天冬氨酸蛋白酶的裂解從而參與炎癥調(diào)節(jié)過程。iPSC-MSCs已經(jīng)成為骨髓源、臍帶源等MSCs和再生藥物治療骨關(guān)節(jié)炎的一種很有前途的替代細(xì)胞來源[8]。iPSC-MSCs治療骨關(guān)節(jié)炎的研究很多，其療效，副作用及其作用機(jī)制也在進(jìn)一步確認(rèn)和深入研究中。
圖3 iPS細(xì)胞分化潛能
參考文獻(xiàn)
[1] https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
[2] Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177. PMID: 18163481.
[3] Finckh A, Gilbert B, Hodkinson B, Bae SC, Thomas R, Deane KD, Alpizar-Rodriguez D, Lauper K. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022 Sep 6. doi: 10.1038/s41584-022-00827-y. Epub ahead of print. PMID: 36068354.
[4] Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998 May;27 Suppl 1:S18-24. doi: 10.1016/s0720-048x(98)00038-2. PMID: 9652497.
[5] Debreova M, Culenova M, Smolinska V, Nicodemou A, Csobonyeiova M, Danisovic L. Rheumatoid arthritis: From synovium biology to cell-based therapy. Cytotherapy. 2022 Apr;24(4):365-375. doi: 10.1016/j.jcyt.2021.10.003. Epub 2022 Jan 26. PMID: 35090806.
[6] El-Jawhari JJ, El-Sherbiny YM, Jones EA, McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM. 2014 Jul;107(7):505-14. doi: 10.1093/qjmed/hcu033. Epub 2014 Feb 10. PMID: 24518000; PMCID: PMC4071294.
[7] Ba?enková D, Trebuňová M, Morochovi? R, Dosedla E, Findrik Balogová A, Ga?parová P, ?iv?ák J. Interaction between Mesenchymal Stem Cells and the Immune System in Rheumatoid Arthritis. Pharmaceuticals (Basel). 2022 Jul 28;15(8):941. doi: 10.3390/ph15080941. PMID: 36015088; PMCID: PMC9416102.
[8] De Miguel MP, Fuentes-Julián S, Blázquez-Martínez A, Pascual CY, Aller MA, Arias J, Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med. 2012 Jun;12(5):574-91. doi: 10.2174/156652412800619950. PMID: 22515979.
成都市武侯區(qū)一環(huán)路南一段24號四川大學(xué)科技創(chuàng)新中心405號
yhsw33399@163.com
028-85217799
